Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Phase 1

Completed

Conditions: Bladder Cancer
Cervical Cancer
Endometrial Cancer
Vaginal Cancer

Interventions: Drug: paclitaxel
Drug: vinorelbine tartrate
Radiation: radiation therapy

First Posted Date: 2004-06-16

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 33

Registration Number: NCT00002949

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer

Phase 3

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-06-16

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 230

Registration Number: NCT00003592

Locations: 🇺🇸
Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States

and more 17 locations

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2004-06-11

Last Posted Date: 2013-07-10

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT00084565

Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-06-11

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00084448

Locations: 🇺🇸
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States

S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: cetuximab
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2004-06-11

Last Posted Date: 2012-11-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 242

Registration Number: NCT00085501

Locations: 🇺🇸
Sletten Regional Cancer Institute, Great Falls, Montana, United States
🇺🇸
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States

and more 159 locations

Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)

Phase 1

Completed

Conditions: Ovarian Serous Cystadenocarcinoma
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Mucinous Cystadenocarcinoma
Stage III Ovarian Epithelial Cancer
Ovarian Undifferentiated Adenocarcinoma
Stage IV Ovarian Epithelial Cancer
Brenner Tumor
Ovarian Carcinosarcoma
Ovarian Clear Cell Cystadenocarcinoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: docetaxel
Biological: bevacizumab

First Posted Date: 2004-06-11

Last Posted Date: 2019-07-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00085358

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Cancer Care Associates-Yale, Tulsa, Oklahoma, United States

and more 13 locations

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Phase 1

Completed

Conditions: Melanoma

First Posted Date: 2004-06-10

Last Posted Date: 2014-03-06

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 103

Registration Number: NCT00084214

Locations: 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸
Piedmont Oncology Specialists, Charlotte, North Carolina, United States
🇺🇸
James Graham Brown Cancer Center - University Of Louisville, Louisville, Kentucky, United States

and more 25 locations

Paclitaxel in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-06-10

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 32

Registration Number: NCT00002632

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 26 locations

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: tamoxifen citrate

First Posted Date: 2004-06-09

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT00003992

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
CCOP - Kalamazoo, Kalamazoo, Michigan, United States

and more 42 locations

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2004-06-09

Last Posted Date: 2014-01-15

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT00006374

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy